Advanced Enzyme Technologies Balance Sheet Health
Financial Health criteria checks 6/6
Advanced Enzyme Technologies has a total shareholder equity of ₹13.0B and total debt of ₹388.6M, which brings its debt-to-equity ratio to 3%. Its total assets and total liabilities are ₹14.4B and ₹1.5B respectively. Advanced Enzyme Technologies's EBIT is ₹1.6B making its interest coverage ratio 103.8. It has cash and short-term investments of ₹4.7B.
Key information
3.0%
Debt to equity ratio
₹388.61m
Debt
| Interest coverage ratio | 103.8x |
| Cash | ₹4.68b |
| Equity | ₹12.99b |
| Total liabilities | ₹1.45b |
| Total assets | ₹14.44b |
Recent financial health updates
Recent updates
Advanced Enzyme Technologies (NSE:ADVENZYMES) Has Affirmed Its Dividend Of ₹1.00
Jul 13
Advanced Enzyme Technologies' (NSE:ADVENZYMES) Returns On Capital Not Reflecting Well On The Business
Apr 08Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Sep 23Advanced Enzyme Technologies (NSE:ADVENZYMES) Could Be Struggling To Allocate Capital
Feb 03Advanced Enzyme Technologies (NSE:ADVENZYMES) Will Want To Turn Around Its Return Trends
Aug 11With EPS Growth And More, Advanced Enzyme Technologies (NSE:ADVENZYMES) Is Interesting
May 13Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Paint A Concerning Picture
Mar 28The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 185%, So Why Not Pay It Some Attention?
Mar 13Don't Ignore The Fact That This Insider Just Sold Some Shares In Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)
Feb 21Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Stock's On An Uptrend: Are Strong Financials Guiding The Market?
Feb 18I Built A List Of Growing Companies And Advanced Enzyme Technologies (NSE:ADVENZYMES) Made The Cut
Feb 03
What Kind Of Investors Own Most Of Advanced Enzyme Technologies Limited (NSE:ADVENZYMES)?
Jan 19What Do The Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES) Tell Us?
Dec 28The Advanced Enzyme Technologies (NSE:ADVENZYMES) Share Price Has Gained 114%, So Why Not Pay It Some Attention?
Dec 13Have Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Insiders Been Selling Their Stock?
Nov 28Are Strong Financial Prospects The Force That Is Driving The Momentum In Advanced Enzyme Technologies Limited's NSE:ADVENZYMES) Stock?
Nov 20Here's Why I Think Advanced Enzyme Technologies (NSE:ADVENZYMES) Might Deserve Your Attention Today
Nov 05What You Need To Know About Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Investor Composition
Oct 21Have Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Insiders Been Selling Their Stock?
Oct 06Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Stocks Shoot Up 31% But Its P/E Still Looks Reasonable
Sep 26Our Take On The Returns On Capital At Advanced Enzyme Technologies (NSE:ADVENZYMES)
Sep 21Does Advanced Enzyme Technologies (NSE:ADVENZYMES) Have A Healthy Balance Sheet?
Sep 08Have Insiders Sold Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Shares Recently?
Aug 26Why We're Not Concerned About Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) Share Price
Aug 21Introducing Advanced Enzyme Technologies (NSE:ADVENZYMES), A Stock That Climbed 60% In The Last Year
Aug 20Advanced Enzyme Technologies Limited's (NSE:ADVENZYMES) P/E Is On The Mark
Aug 07Are Insiders Buying Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Stock?
Jul 29How Does Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Fare As A Dividend Stock?
Jul 17Advanced Enzyme Technologies Limited (NSE:ADVENZYMES) Looks Like A Good Stock, And It's Going Ex-Dividend Soon
Jul 04Do Advanced Enzyme Technologies's (NSE:ADVENZYMES) Earnings Warrant Your Attention?
Jun 28Financial Position Analysis
Short Term Liabilities: ADVENZYMES's short term assets (₹7.4B) exceed its short term liabilities (₹874.0M).
Long Term Liabilities: ADVENZYMES's short term assets (₹7.4B) exceed its long term liabilities (₹577.8M).
Debt to Equity History and Analysis
Debt Level: ADVENZYMES has more cash than its total debt.
Reducing Debt: ADVENZYMES's debt to equity ratio has reduced from 7.2% to 3% over the past 5 years.
Debt Coverage: ADVENZYMES's debt is well covered by operating cash flow (341.5%).
Interest Coverage: ADVENZYMES's interest payments on its debt are well covered by EBIT (103.8x coverage).